MLYNARCIKOVA, Miroslava, Jana BALCARKOVA, Pavla MICKOVA, Vlastimil SCUDLA, Tomas PIKA, Jaroslav BACOVSKY, Jiri MINARIK, Eva JANOUŠOVÁ and Marie JAROSOVA. Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse. Clinical Lymphoma, Myeloma and Leukemia. Dallas: CIG Media Group, 2016, vol. 16, No 6, p. 358-365. ISSN 2152-2650. Available from: https://dx.doi.org/10.1016/j.clml.2016.02.038.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse
Authors MLYNARCIKOVA, Miroslava (203 Czech Republic), Jana BALCARKOVA (203 Czech Republic), Pavla MICKOVA (203 Czech Republic), Vlastimil SCUDLA (203 Czech Republic), Tomas PIKA (203 Czech Republic), Jaroslav BACOVSKY (203 Czech Republic), Jiri MINARIK (203 Czech Republic), Eva JANOUŠOVÁ (203 Czech Republic, guarantor, belonging to the institution) and Marie JAROSOVA (203 Czech Republic).
Edition Clinical Lymphoma, Myeloma and Leukemia, Dallas, CIG Media Group, 2016, 2152-2650.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.494
RIV identification code RIV/00216224:14110/16:00090553
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.clml.2016.02.038
UT WoS 000378029200011
Keywords in English FICTION; MYC; TRAIL-R1; TRAIL-R2; genetic changes
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 11/11/2016 10:26.
Abstract
This retrospective study of 62 patients with multiple myeloma examined at 2 different phases (diagnosis and progression/relapse), revealed chromosome 8 aberrations in 24 (38.7%) patients at diagnosis and in 29 (46.8%) patients at progression/relapse. We did not confirm a significant increase of chromosome 8 aberrations at progression/relapse; however, we confirmed the heterogeneity of the aberrations and their poor prognostic impact on overall survival. Background: The genome of multiple myeloma (MM) clonal plasma cells is characterized by genetic changes of prognostic importance. Disease progression is accompanied by a number of secondary chromosomal aberrations including chromosome 8. We focused on the detection of chromosome 8 aberrations in patients with MM who were examined at 2 different phases: diagnosis and progression/relapse. Patients and Methods: A total of 62 patients with MM were examined at the time of diagnosis and at relapse/progression. The median age was 64 years (range, 39-78 years); the study included 29 males and 33 females. We analyzed bone marrow samples for detecting aberrations on chromosome 8 by the fluorescence immunophenotyping and interphase cytogenetics as a tool for the investigation of neoplasms (FICTION) and fluorescence in situ hybridization methods with specific probes. Results: Chromosome 8 aberrations were detected in 24 (38.7%) patients at diagnosis and in 29 (46.8%) patients at progression/relapse. Only 5 (8%) patients developed additional chromosome 8 changes at progression/relapse. The aberrations were heterogeneous, involving numerical and structural changes of the MYC gene. Aberrations of the short arm of chromosome 8, involving the genes TRAIL-R1/-R2, were less frequent (4 of 62 patients, 6.4%). All aberrations of chromosome 8 were accompanied with additional changes and with an advanced clinical phase of the disease. This finding significantly influenced the overall survival of patients. Conclusion: In the current study, chromosome 8 aberrations were highly heterogeneous, were presented at diagnosis in patients with advanced clinical stage, and were associated with worse overall survival. We have not confirmed the increase of frequency aberration of chromosome 8 in disease progression. The findings demonstrate the importance of fluorescence in situ hybridization examination of chromosome 8 in newly diagnosed patients with MM.
PrintDisplayed: 7/9/2024 17:58